Trial Profile
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRIMA
- Sponsors GlaxoSmithKline; GSK; TESARO
- 02 Apr 2024 Planned End Date changed from 29 Mar 2024 to 25 Sep 2024.
- 06 Nov 2023 Results Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment, published in the International Journal of Gynecological Cancer
- 06 Jun 2023 Results of post-hoc analysis assessing factors associated with long-term progression-free survival, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.